reports
- Carole Braudeau
- Carole Braudeau
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Fabrice Farigoule
Yet another round of financing
Yet another round of financing FINANCING ISSUE Crossject has raised €5m through the issuance of convertible bonds. Management indicates that this financing round should meet funding requirements until the EUA is granted. We will incorporate this financing, considering the benefits of the additional cash and the potential for further dilution. However, due to the amount and nature of the issuance, the impact on our figures will be limited. FACT Crossject has announced the completion of a €5m...
CROSSJECT lève 5 millions d'euros auprès de Vatel Capital
CROSSJECT lève 5 millions d'euros auprès de Vatel Capital Communiqué de presse CROSSJECT lève 5 millions d'euros auprès de Vatel Capital DIJON, France – 14 novembre 2025 (20H30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgencefondés sur sa technologie propriétaire d’auto-injecteurs sans aiguille ZENEO®, en phase avancée de développement et d'enregistrement de ZEPIZURE®, un injectable pour la prise en charge des crises d'épilepsie, annonce aujourd'hui la finalisation d'une levée de fond...
CROSSJECT completes €5 million financing with Vatel Capital
CROSSJECT completes €5 million financing with Vatel Capital Press release CROSSJECT completes €5 million financing with Vatel Capital DIJON, France – November 14th, 2025 (8.30 PM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company that develops products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, in the advanced stages of development and registration of ZEPIZURE®, an injectable for the treatment of epileptic seizures, today announces the completion of a €5 million fund raising fully subscribed by fun...
- Carole Braudeau
Credit Morning 11/13/2025
Carrefour: Saadé family acquires stake, Peninsula exits|Emeria: an equity fundraising to enable bond refinancing?|Advanz Q3 25 results: Adj. EBITDA drops yoy and net leverage increases further – but not surprising|grenke Q3 25 results: Good operational performance YTD, but loss rate and NPLs increase|Finnair: no surprises on the FY 2026-2029 targets at first sight|
- Carole Braudeau
Morning Crédit 13/11/2025
Carrefour : entrée de la famille Saadé au capital et sortie de Peninsula|Emeria : une levée d’equity pour permettre le refinancement des obligations ?|Advanz Q3 25 results: Adj. EBITDA drops yoy and net leverage increases further – but not surprising|grenke Q3 25 results: Good operational performance YTD, but loss rate and NPLs increase|Finnair: no surprises on the FY 2026-2029 targets at first sight|
Diasorin S.P.A: 1 director
A director at Diasorin S.P.A bought 5,000 shares at 61.025EUR and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
CROSSJECT : Information relative au nombre total de droits de vote et ...
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 06 novembre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composan...
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
ETL EUTELSAT COMMUNICATIONS SA
NK IMERYS SA
RNO RENAULT SA
DAI DAIMLER AG
EN BOUYGUES SA
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
VOW3 VOLKSWAGEN AG PREF
RACE FERRARI NV
GEST GESTAMP AUTOMOCION S.A.
NEXI NEXI S.P.A.
STLA STELLANTIS N.V.
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
KPN ROYAL KPN NV
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Carole Braudeau
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
ETL EUTELSAT COMMUNICATIONS SA
NK IMERYS SA
RNO RENAULT SA
DAI DAIMLER AG
EN BOUYGUES SA
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
VOW3 VOLKSWAGEN AG PREF
RACE FERRARI NV
GEST GESTAMP AUTOMOCION S.A.
NEXI NEXI S.P.A.
STLA STELLANTIS N.V.
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Christophe-Raphaël Ganet
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.